An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
NO_LONGER_AVAILABLE
Status
Conditions
- Clear Cell Kidney Cancer
- Kidney Cancer
- Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Interventions
Sponsor
Lynkcell Europe